Metreleptin in Anorexia Nervosa

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions
Anorexia Nervosa
Interventions
DRUG

Metreleptin

"Metreleptin 3 mg is packaged in 3 ml Type I glass vials with chlorobutyl rubber stoppers, and aluminum seals with plastic flip-off caps. The vials are stored in refrigerator (2 - 8°C) and protected from light. Metreleptin for injection is a sterile, white, solid lyophilised cake.~Prior to patient use, the content of a vial is reconstituted with 0.6 ml of water for injection for a final formulation of 10 millimolar (mM) glutamic acid, 2% glycine, 1% sucrose, 0.01% polysorbate 20, potential hydrogen (pH) 4.25. The resulting solution is administered by subcutaneous injection."

DRUG

Sodium chloride

The placebo will consist of sterile 0.9% saline (Sodium chloride), drawn up from a 10 ml i.v. vials. The placebo will be administered as an subcutaneous injection in an identical procedure as the metreleptin verum.

Trial Locations (1)

8091

RECRUITING

Eating Disorder Unit, Clinic of Consultation-Liaison Psychiatry and Psychosomatic Medicine, University Hospital Zurich, Zurich

All Listed Sponsors
lead

Gabriella Milos

OTHER